3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Glioblastoma
5
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Rectal Neoplasms
4
Neoplasms
4
Head and Neck Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Glioma
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Brain Neoplasms
3
Astrocytoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Lung Neoplasms
2
Carcinoma, Squamous Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Sinonasal Squamous Cell Carcinoma
1
Rhabdomyosarcoma
1
Recurrence
1
Radiation Injuries
1
Prostatic Neoplasms
1
Prostate Adenocarcinoma
1
Postoperative Complications
1
Pilonidal Sinus
1
Interventions
pembrolizumab
52
Paclitaxel
19
Cisplatin
14
Carboplatin
14
lenvatinib
10
Docetaxel
8
Saline Solution
7
Capecitabine
7
Pemetrexed
6
Oxaliplatin
6
Gemcitabine
6
Fluorouracil
6
Leucovorin
5
Albumin-Bound Paclitaxel
5
olaparib
4
belzutifan
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
patritumab deruxtecan
3
Glucose
3
Acetaminophen
3
liposomal doxorubicin
2
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Doxorubicin
2
Dexamethasone
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Surgical Procedures, Operative
×
90 days
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled